People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology, Pharmaceuticals, Business Services
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. | — | Biotechnology | Series B | $15.9M | $259.1M | 2022 |
| Centry Pharma, Inc. | — | Pharmaceuticals | Series A | $11.3M | $234.0M | 2021 |
| Scribl, Inc. | — | Business Services | Pre-Seed | $665K | $942K | 2024 |
Matthew Kaplan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Kaplan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ron Bentsur | 2 | 4 |
| Kenneth Hoberman | 2 | 3 |
| Shay Shemesh | 2 | 2 |
| James Oliviero | 2 | 2 |
| Enrique Poradosu | 2 | 2 |
| Uri Ben Or | 1 | 2 |
| Marty Young | 1 | 2 |
| Michael Carson | 1 | 1 |
| Kenneth Solomon | 1 | 1 |
| Matt Lowe | 1 | 1 |
| Jeffrey Sparr | 1 | 1 |
| Jeff Sparr | 1 | 1 |
| Lewis Klessel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.